Inion biodegradable meniscus screw:
This article was originally published in Clinica
Finnish firm Inion has received US FDA 510(k) clearance for its biodegradable Trinion meniscus screw for use in knee cartilage repair. The product is based on the Tampere firm's Optima family of biomaterials, made by blending rigid and elastic polymer components to create implants with the most appropriate strength, malleability and degradation profiles to meet their specific clinical requirements. The screw also includes a dual thread screw for optimal fixation with a headless design to allow complete insertion into the meniscus to avoid chondral lesion development. The product will be distributed in the US by Pompano Beach, Florida-based Lifeline Biotechnologies.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.